News >

Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Sep 04, 2019

Thomas Powles, MD, MBBS, MRCP, director of Barts Cancer Centre

Thomas Powles, MD, MBBS, MRCP

The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication